Study of Immune Response in Obesity and Type 2 Diabetes (IMMUNOBEDIA)
Obesity, Type 2 Diabetes, Healthy Volunteers
About this trial
This is an interventional other trial for Obesity focused on measuring obese patients, obese patients with type 2 diabetes, healthy volunteers
Eligibility Criteria
Inclusion Criteria:
- Patient-control who have given written informed consent Patient-control who are covered by the National Health Insurance Agency Patient-control > 18 years old
The criteria to classify patients into groups will be as follows:
Group 1- Obese diabetics BMI > 30 Kg /m2 AND fasting glycemia > 1.26 g/L AND Triglycerides >1.5g/L AND HDL <0.4g/L (men), <0.5g/L (women) Group 2- Obese non-diabetics without metabolic syndrome BMI > 30 Kg /m2 AND fasting glycemia < 1.10 g/L AND Triglycerides <1.5g/L AND HDL >0.4g/L (men), >0.5g/L (women) Group 3- Healthy Subjects BMI < 25 Kg/m² AND fasting glycemia < 1.10g/L AND Triglycerides <1.5g/L
Exclusion Criteria:
- Persons not covered by the National Health Insurance Agency Patients who presented a recent infection, or cancer or patients treated with corticosteroids or anti-inflammatory drugs. Patients with diabetes following an overload disease (hemochromatosis) or due to a disease of the pancreas Chronic infection Pregnant women Patients on the following treatments (glitazone: Actos, Avendia; GLP1 Agonist: Byetta, Victoza; Fibrates) Patients presenting severe renal insufficiency with clearance<30ml/min
Sites / Locations
- CHU de Dijon
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
obese patients
obese patients with type 2 diabetes
healthy volunteers
(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L